Some Good News in Alzheimer's Treatments

The video discusses a new Alzheimer's treatment, lecanumab, which shows promise in slowing disease progression. A phase three trial involving 1795 participants revealed a 27% reduction in clinical decline compared to placebo after 18 months. However, the clinical significance of this reduction is debated due to potential side effects like brain swelling and bleeding. The drug is under priority review by the FDA and has been submitted for approval in Japan. Experts are cautiously optimistic, but further research is needed to confirm its efficacy and explore other treatment options, including targeting Tau protein.

What is the significance of the 0.45 point difference in scores between the placebo and drug groups?

What role do amyloid and Tau proteins play in Alzheimer's disease according to the text?